NOW THAT JUNE IS ALMOST THROUGH, WHEN IS MY SITC ABSTRACT DUE?
In Five (5) Weeks!
Submit your abstract by Aug. 1, 2017, at 5 p.m. PT for a chance to present your work to over 2,500 of the world’s leading oncologists, researchers and luminaries in the field at the SITC 32nd Annual Meeting. This is the premier conference dedicated solely to cancer immunotherapy where cutting-edge research is presented. Young investigator abstract submitters are also eligible for one of 32 travel awards, including the coveted SITC Presidential Award.
Will you have novel, innovative data collected or analyzed after the official abstract deadline? Complete an application by Aug. 1, 2017, at 5 p.m. PT and you may be invited to submit a late-breaking abstract between Aug. 25 and Sept 14.
Are you developing biomarkers or related technologies? Submit an application by Aug. 1, 2017, at 5 p.m. PT to be considered for a presentation spot in the Immuno-Oncology Biomarkers: Today’s Imperatives for Tomorrow’s Needs pre-conference program, scheduled on Wednesday, Nov. 8.
SITC connectED ADDS NEW OPEN ACCESS ONLINE EDUCATIONAL ACTIVITIES
This new, interactive online educational activity provides an overview of the immune system and is hosted by Dr. Christian Capitini (University of Wisconsin). This course focuses on mechanisms used by the immune system to eliminate foreign pathogens and cancerous cells. The activity provides the foundational knowledge to understand how the immune system can be harnessed to treat cancer through immunological therapies. CE Credits - Maximum of 1.0 AMA PRA Category 1 Credit(s)™, CNE Credit - 1.0 Contact Hour, CPE Credit - 1.0 Contact Hour (0.10 CEU) for physicians.
This activity is the online version of the live presentation delivered at the 2017 Genitourinary Cancers Symposium. Participants will gain insight on the role of immune checkpoint inhibitors for the treatment of advanced bladder cancer. Faculty summarize their symposium presentations and share commentary on results of recent clinical trials, patient selection, patterns of response, adverse event management and ongoing trials. A downloadable slide set from the live meeting accompanies each video. CME Credits - Maximum of 0.5 AMA PRA Category 1 Credit(s)™ for physicians.
SITC is continuing its partnership with Medscape to develop online activities around current issues in immunotherapy. In this newest activity, Dr. Michael Atkins (Georgetown-Lombardi Comprehensive Cancer Center) and Dr. Toni Choueiri (Dana-Farber Cancer Institute) discuss the latest advances in the use of immunotherapy in patients with mRCC. CME Credits - Maximum of 0.75 AMA PRA Category 1 Credit(s)™ for physicians.